增长激素释放激素受体的信号机制
Gabor Halmos1, Zsuzsanna Szabo2, Eva Juhasz3
1Department of Biopharmacy, Faculty of Pharmacy, University of Debrecen, Debrecen, Hungary; Veterans Affairs Medical Center, Endocrine, Polypeptide and Cancer Institute, Miami, FL, United States.
Vitamins and hormones
|September 17, 2023
概括
增长激素释放激素 (GHRH) 和它的受体 (GHRH-R) 在激素分泌中发挥关键作用. 研究探讨了GHRH-R拼接变体及其在各种疾病中的治疗潜力.
科学领域:
- 内分泌学和分子生物学
- G蛋白结合受体 (GPCR) 研究研究
- 癌症生物学和治疗目标
背景情况:
- 增长激素释放激素 (GHRH) 通过GHRH受体 (GHRH-R) 刺激垂体生长激素 (GH) 的分泌.
- GHRH-R是一种G蛋白结合受体,具有7个跨膜域.
- 已在人类瘤和额外垂体组织中确定了GHRH-Rs的拼接变体 (SV).
研究的目的:
- 审查GHRH受体的表达和功能及其在各种组织中的拼接变体.
- 阐明GHRH受体的激活,分子机制和信号通路.
- 讨论GHGH类型的治疗应用.
主要方法:
- 识别和cDNA测序的GHRH-R拼接变体 (SVs).
- 对拼接变种1 (SV1) 功能进行评估,包括cAMP信号传递和线粒发生性活性.
- 对关于GHRH受体表达,功能和治疗应用的现有文献的审查.
主要成果:
- 拼接变体1 (SV1) 与全长GHRH-R具有很高的相似性,并保留了功能活性.
- 在GHRH刺激时,SV1会引起cAMP信号传递和代性活性.
- 广泛的研究已经探索了用于各种临床应用的GHGH激动剂和对抗剂.
结论:
- GHRH受体及其拼接变体在各种组织中表达,具有超出 pituitary 的潜在功能.
- 了解GHRH-R信号通路对于开发向疗法至关重要.
- GHRH类似物对治疗内分泌学,瘤学,代谢障碍和神经退行性疾病的条件具有前景.
相关概念视频
Endocrine Signaling
64.4K
Endocrine cells produce hormones to communicate with remote target cells found in other organs. The hormone reaches these distant areas using the circulatory system. This exposes the whole organism to the hormone but only those cells expressing hormone receptors or target cells are affected. Thus, endocrine signaling induces slow responses from its target cells but these effects also last longer.
64.4K
Insulin: The Receptor and Signaling Pathways
1.3K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.3K
Secondary Messengers in Hormone Action
2.3K
Water-soluble hormones cannot cross the plasma membrane, so they rely on protein receptors that span the membrane to trigger intracellular signaling pathways. These pathways then activate second messengers inside the cell, including cAMP or calcium ions.
Many hormones bind to transmembrane G protein-coupled receptors that connect to regulatory G proteins. These G proteins can then activate enzymes such as adenylyl cyclase or phospholipase C. Adenylyl cyclase converts ATP to cAMP, activating...
Many hormones bind to transmembrane G protein-coupled receptors that connect to regulatory G proteins. These G proteins can then activate enzymes such as adenylyl cyclase or phospholipase C. Adenylyl cyclase converts ATP to cAMP, activating...
2.3K
Cell-surface Signaling
51.9K
Hormones—or any molecule that binds to a receptor, known as a ligand—that are lipid-insoluble (water-soluble) are not able to diffuse across the cell membrane. In order to be able to affect a cell without entering it, these hormones bind to receptors on the cell membrane. When a first messenger, a hormone, binds to a receptor, a signal cascade is set off, causing second messengers, proteins inside the cell, to become activated, resulting in downstream effects.
51.9K
Amplifying Signals via Enzymatic Cascade
8.5K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.5K
TGF - β Signaling Pathway
7.4K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.4K


